Oral cancer, a significant global health concern, remains a challenging disease with high mortality rates. Despite advancements in treatment, late diagnosis and lack of effective biomarkers hinder patient outcomes. To address this, our study investigates the potential of specific genes (MB, TP53, CENPA, BUB1B, MAD2L and ZWINT) and microRNAs (hsa-mir-607, hsa-mir-556-5p, hsa-mir-1225-3p, hsa-mir-361-3p) as prognostic markers and therapeutic targets for oral cancer. We hypothesize that these genes and miRNAs play crucial roles in regulating cell cycle progression, DNA damage repair, and apoptosis in oral cancer cells. By analyzing their expression patterns in oral cancer tissues and adjacent normal tissues, we aim to identify potential biomarkers for early diagnosis and prognosis. Additionally, we explore the potential of targeting these molecules to enhance the efficacy of radiation therapy and improve patient outcomes. Our study contributes to the comprehension of the molecular processes underlying oral cancer and provides insights into the development of novel therapeutic strategies based on personalized medicine.
No takes yet. Share an insight, caveat, or question.
Khoushab et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: